K12CA086913 Renewal - Paul Calabresi Award in Clinical Oncology Research

描述(由申请人提供)：保罗·卡拉布雷西临床肿瘤学研究奖(PCACOR)的目的是培养高素质的癌症临床研究人员，他们被称为学者，他们可以通过学习与临床和基础科学家的多学科团队沟通和协调，使用最先进的实验室分析来个性化癌症治疗，从而独立设计、管理和完成癌症临床试验。具体目标是：1)为已完成临床培训的肿瘤内科医生和博士临床医生(护士、药剂师、临床心理学家、流行病学家、口腔外科医生)提供灵活的个人发展计划；2)通过计划学者的多重指导，促进跨学科培训、交流和互动；3)为已完成临床研究的PCACOR学者提供持续的指导，以确保他们成功过渡到临床研究独立。强大的临床和基础科学导师在所有肿瘤学临床学科以及癌症基础科学方面提供出色的培训和榜样。PCACOR由一个多学科咨询委员会负责监督，该委员会由项目负责人马德琳·A·凯恩(医学博士)、医学肿瘤学教授马德琳·A·凯恩和安德鲁·索伯恩博士(UCCC药理学系教授兼主任、副主任)领导。培训期限从两年到七年，包括CCTSI临床科学项目和UCD研究生院提供的负责任的研究行为和课程等核心要求。每个学者完成一个基础科学项目，并设计至少一项癌症临床试验。学者们在培训的最后一年内提交了NIH风格的拨款申请。我们的过往记录证明了最终的成功。共有15名初级教员接受了PCACOR学者培训，其中9人在本资助期间(42份申请中的9份)。13名学者仍然是科罗拉多大学丹佛安舒茨医学院(UCD-AMC)的教员；6名学者已经晋升，所有人都有多份同行评议的出版物，包括临床和基础科学。8个已经从NIH，DOD ACS和/或Komen基金会获得了同行审查的资金。所有人都设计了至少一项癌症临床试验，几名PCACOR毕业生领导国家癌症临床试验、癌症研究培训计划和临床癌症研究计划。我们的PCACOR成功地培养出了未来的翻译癌症临床研究人员。

DESCRIPTION (provided by applicant): The purpose of this Paul Calabresi Award in Clinical Oncology Research (PCACOR) is to prepare highly qualified cancer clinical researchers called Scholars who can independently design, manage and complete cancer clinical trials by learning to communicate and coordinate with multidisciplinary teams of clinical and basic scientists using state-of-the-art laboratory analyses to personalize cancer treatment. Specific objectives are to: 1) Provide a flexible Individual Development Program for oncology medical doctors and Ph.D. clinicians (nurses, pharmacists, clinical psychologists, epidemiologists, oral surgeons) who have completed their clinical training and basic research scientists who are committed to a translational clinical cancer research career in an academic setting; 2) Foster interdisciplinary training, communication and interaction through multiple mentoring of program scholars; 3) Create an ongoing mentorship to the completed PCACOR Scholars to ensure their successful transition to clinical research independence. Strong clinical and basic science mentors provide exceptional training and role models in all oncology clinical disciplines as well in cancer basic science. A multidisciplinary Advisory Committee oversees the PCACOR directed by Program Leaders, Madeleine A. Kane, MD, Ph.D., Professor of Medical Oncology, and Andrew Thorburn, Ph.D., Professor and Chair, Department of Pharmacology, Deputy Director, UCCC. Training period lasts from two to seven years and includes Core requirements such as Responsible Conduct of Research and coursework provided by CCTSI Clinical Science Program and the UCD Graduate School. Each Scholar completes a basic science project and also designs at least one cancer clinical trial. Scholars submit an NIH style grant application within the last yea of training. The ultimate success is demonstrated by our track record. A total of fifteen junior faculty have trained as PCACOR Scholars, nine during the current funding period (out of 42 applications). Thirteen Scholars remain faculty members at University of Colorado Denver Anschutz Medical Campus (UCD-AMC); six have been promoted, all have multiple peer-reviewed publications, both clinical and basic science. Eight have obtained peer-reviewed funding from NIH, DOD ACS and/or Komen Foundation. All have designed at least one cancer clinical trial, and several PCACOR graduates lead national cancer clinical trials, cancer research training programs and clinical cancer research programs. Our PCACOR successfully produces the translational cancer clinical researchers of the future.